Result
€1.1m €1.1m
Back in profit in 2025, after a loss of €151,785 in 2024.
CONTIPHARMA
Lifetime
18 annual accounts with figures on one time axis, 24 filings since 2000peak €2.7m (2025)
€2.7m▲ €2.8m
lowest -€151,785 (2024)
€1.1m▲ €1.2m
peak €3.2m (2025)
€3.2m▲ 49.3%
€4.0m▼ 20.7%
peak 1.3 FTE (2025)
1.3 FTE▲ 30.0%
Board3 names since 2017
2 directors and 1 other
Documentsfilings and deeds
14-10-202675 days late
2025abbreviated format
Gross margin from -€95,623 to €2.7mBack to profit: €1.1mStaff from 1 FTE to 1.3 FTEEquity from €2.2m to €3.2mDebts from €5.0m to €4.0m
Key points
from the 2025 annual accountsInvestments
€84,243 5.3 × depreciation
Green is investment, beige is depreciation.
Staff
3 employees on 31-12-2025
In 2025, 2 people joined and nobody left.
Liquidity
3.34 was 1.20 in 2024
Short-term debts fell from €1.8m to €1.0m.
Filings
24 annual accounts 75 days
Latest accounts filed late: after the legal deadline.
Subsidiaries
-€875,528
Subsidiary with negative equity. · loss of €64,388 in 2025.
Checked score
Outside the general model
Holding: general score not applicable
The company has a registered holding activity. Financial fixed assets make up more than half of its assets. The general model for operating companies does not fit such a balance sheet, so there is no score and no financial strength.
Bankruptcy probability within 12 months
The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0466820220
Company renamed from GOM HOLDING to CONTIPHARMА
Resignations: (director) and (director) · Appointments: (director) and (director) · “Exercer le commerce de gros de produits et matériels en relation avec la pharmacie, la biologie, la droguerie…” (deed in French) · Gazette deed
2 directors reappointed
(managing director) and · Permanent representative: · General meeting of 13-06-2017 · Gazette deed
First establishment
Rue de l'Environnement 22, Seraing
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| CONTIPHARMA Seraing | €7.2m | €2.7m | 44.8% | 1.3 |
| SYNAPHARM INDUSTRIAL SYNTHESIS Grâce-Hollogne | €6.1m | €2.7m | 61.1% | 1.7 |
| EURAMEDICS HOSPITAL PRODUCT SERVICES Diepenbeek | €4.9m | €1.8m | 80.9% | 1.6 |
| LUCIMED Wavre | €4.8m | €1.5m | 54.7% | 1 |
| VESALE PHARMACEUTICA Gembloux | €4.0m | €2.2m | 77.1% | 2.8 |
| HEFRA Turnhout | €10.7m | €1.2m | 98.9% | 3 |
| PROFIPLUS Hasselt | €5.2m | €0.8m | 24.6% | 1.5 |
These companies have the same main activity as CONTIPHARMA: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €4m and €11m, founded between 1994 and 2005.
Official details
Source: KBO- Status
- Active since 09-09-1999Normal situation
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460and 3 others
- Joint committee
- 200Auxiliary committee for white-collar workers · annual accounts 2024
- Establishment unit
- 2.092.169.5414100 Seraing, since 14-09-1999
- Financial year end
- 31 December
- Peppol
- Reachable since 03-12-2025
Annual accounts 2025
- ≈ €11.0mestimated
- €7.2m▲ 0.4%
- Employeeson 31-12-2025
- 3▲ 200%
- Filing
- Filed on 14-10-2026
Insights on CONTIPHARMA
CONTIPHARMA files the abbreviated format. That format states no turnover. The gross margin rose from -€4,267 in 2007 to €2.7m in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about CONTIPHARMA
- What is the company number of CONTIPHARMA?
- The company number of CONTIPHARMA is 0466.820.220. The VAT number is the same number with BE in front: BE 0466.820.220.
- Where is CONTIPHARMA based?
- The registered office is at Rue de l'Environnement 22, 4100 Seraing.Company details
- What does CONTIPHARMA do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of CONTIPHARMA?
- CONTIPHARMA is a public limited company (NV).
- When was CONTIPHARMA founded?
- CONTIPHARMA was founded on 09-09-1999.
- Is CONTIPHARMA still active?
- Yes, CONTIPHARMA is an active enterprise in the KBO register.
- How many employees does CONTIPHARMA have?
- CONTIPHARMA had an average of 1.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does CONTIPHARMA fall under?
- In its 2024 annual accounts, CONTIPHARMA states joint committee 200 (Auxiliary committee for white-collar workers).
- What is the turnover of CONTIPHARMA?
- The turnover in financial year 2025 is ≈ €11.0m. This figure is estimated from the gross margin of €2.7m and 96 comparable companies (NACE 46). It probably lies between €6.7m and €19.0m.
- Is CONTIPHARMA profitable?
- In financial year 2025, CONTIPHARMA made a profit of €1.1m.
- Where can I find the annual accounts of CONTIPHARMA?
- CONTIPHARMA filed 24 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of CONTIPHARMA due?
- CONTIPHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See what changed in the latest annual accounts.What changed See whether the workforce is growing and whether people stay.Employer check
See how customers, suppliers and banks see your own company and what to improve first.